Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Trump dishes on Milley clash over leaving military...
TikToker knocks Harris’ ‘weird’ take on never released...
‘Who wouldn’t want it?’: Netanyahu open to receiving...
Supreme Court lets Trump’s ‘wrecking ball’ federal job...
Biden’s strange use of teleprompter in donor’s home...
Tariff case pits Cato Institute against Trump over...
GREGG JARRETT: CIA report makes it clear Trump...
State Department investigating Rubio AI impersonator who contacted...
DOJ lands legal victory as federal judge allows...
Senate Republican moves to give US an edge...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

by admin November 13, 2024
November 13, 2024
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

PRISM MarketView a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. ( NASDAQ: CRDL, TSX: CRDL ) has been added to the PRISM Emerging Biotech Index, which spotlights companies leading innovation and creating market impact within the biotech sector. Cardiol’s focus on anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate CardiolRx, positions it as a pioneer in addressing major unmet needs in cardiac care.

The US FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, which includes recurrent pericarditis. Cardiol’s MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the Phase II MAvERIC-Pilot study (NCT05494788), the Phase II/III MAVERIC-2 trial, and the planned Phase III MAVERIC-3 trial. The MAVERIC-2 trial will evaluate the impact of CardiolRx in recurrent pericarditis patients following the cessation of interleukin-1 blocker therapy. MAVERIC-2 is expected to initiate in Q4 2024 at major pericardial disease centers across the United States and Europe, with results anticipated ahead of the company’s planned pivotal Phase III MAVERIC-3 trial.

Recurrent pericarditis affects approximately 38,000 patients in the United States annually who have experienced at least one recurrence. The global pericarditis market was valued at $2.44 billion in 2023 and is projected to grow at a CAGR of 5.24% during the forecast period of 2024-2032, reaching $3.87 billion by 2032.

In addition, Cardiol is advancing CRD-38, a proprietary subcutaneously administered therapy for heart failure. Cardiol’s broad IP portfolio and regulatory pathway focus, including FDA and European Medicines Agency orphan designations, bolster its strong market positioning. The company is debt-free and well-capitalized to achieve corporate milestones into 2026.

For more information on Cardiol Therapeutics and the PRISM Emerging Biotech Index , visit prismmarketview.com .

About Cardiol Therapeutics
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis and heart failure.

Cardiol has received Investigational New Drug Application authorization from the U.S. Food and Drug Administration (FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath and fatigue and results in physical limitations, reduced quality of life, emergency department visits and hospitalizations, comprises the Phase II MAvERIC-Pilot study (NCT05494788), the Phase II/III MAVERIC-2 trial, and the planned Phase III MAVERIC-3 trial. The ARCHER trial (NCT05180240) is a Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, which includes recurrent pericarditis.

Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.

For more information about Cardiol Therapeutics, please visit cardiolrx.com .

About PRISM MarketView
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small-cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.

PRISM MarketView does not provide investment advice.

Disclaimer: This communication was produced by PRISM MarketView (PMV). PMV is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy or a recommendation of any security. PMV may be compensated by respective clients for publicizing information relating to its clients’ securities.
See prismmarketview.com/disclaimer/

Contact:
PRISM MarketView
info@prismmarketview.com
646-863-6341

News Provided by GlobeNewswire via QuoteMedia

This post appeared first on investingnews.com

previous post
‘Trump trade’ returns for second week as bitcoin, Tesla, stocks surge
next post
First Helium Initiates Process to License & Drill the Leduc Anomaly

You may also like

Canadian Investment Regulatory Organization Trade Resumption – FYL

April 18, 2025

Michael Campbell: Gold, Uranium, Oil/Gas — Bullish as...

February 3, 2025

High Grade surface silver results up to 920g/t...

May 15, 2025

Anteros Identifies High-Grade Copper-Gold Targets at the Strickland...

May 21, 2025

Results of Channel Sampling Program at Halleck Creek

May 8, 2025

Couloir Capital is Pleased to Announce it has...

September 25, 2024

Group Eleven Intersects 7.5m of 20.1% Zn+Pb and...

March 25, 2025

QX Resources Limited (ASX: QXR) – Trading Halt

October 24, 2024

WESTERN COPPER AND GOLD WELCOMES FEDERAL FUNDING FOR...

September 23, 2024

xReality Group Limited Chairman’s Address 2024 Annual General...

November 22, 2024

Recent Posts

  • Trump dishes on Milley clash over leaving military equipment in Afghanistan: ‘I knew he was an idiot’
  • TikToker knocks Harris’ ‘weird’ take on never released interview: ‘Not good’
  • ‘Who wouldn’t want it?’: Netanyahu open to receiving stealth bombers, bunker-busters from US
  • Supreme Court lets Trump’s ‘wrecking ball’ federal job cuts proceed while legal fight continues
  • Biden’s strange use of teleprompter in donor’s home infuriated supporters, dashed expectations

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (818)
    • Investing (2,487)
    • Politics (3,085)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.